GlassScriptPhysician profile
Orly Matheson
NPI 1659481141
$1,045.68
in general payments reported to CMS, 2019-2025
17 companies · $161 in 2025
The $161 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $78.36 · 2022: $164 · 2023: $289 · 2024: $353 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $802.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $150.00 | 2024 | |
| Novo Nordisk INC | $133.00 | 2021-2023 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $97.25 | 2025 | Lokelma |
| Abbott Laboratories | $85.30 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $68.92 | 2021-2023 | Xarelto |
| Exact Sciences Corporation | $59.49 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $58.96 | 2023 | |
| Glaxosmithkline, LLC. | $55.37 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Madrigal Pharmaceuticals | $46.87 | 2025 | Rezdiffra |
| Lilly USA, LLC | $41.49 | 2022 | |
| Abbvie INC. | $34.07 | 2022-2023 | |
| Biohaven Pharmaceuticals, INC. | $25.02 | 2021 | |
| Atricure, INC. | $24.80 | 2023 | |
| Amgen INC. | $18.09 | 2023 | Otezla, Repatha |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $17.48 | 2023 | Watchman Flx |
| Genentech USA, INC. | $4.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Orly Matheson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.